Update: Market Chatter: Micron Technology's Taiwan Workers Authorize Strike Over Bonus Dispute
MT newswire2026/10/08 08:2104:21 AM EDT, 10/08/2026 (MT Newswires) -- (Updates to add Micron Technology's comment in the fourth paragraph.) Members of a union representing workers at Micron Technology's (MU) Taoyuan operations in Taiwan have authorized a strike over the company's bonus scheme, Reuters reported Wednesday. The union's 1,994 members, or 99% of those who voted, backed the strike, Reuters reported, adding that the timing and details of any work stoppage have yet to be decided. The Taoyuan union said Micron's fiscal 2026 bonus package did not address its demand for a permanent profit-sharing system and criticized the company for announcing the rewards while mediation was ongoing, Reuters reported. Micron spokesperson said it respects employees' legal rights and the mediation process and will continue talks with the unions, including another mediation session with the Micron Memory Taiwan Union later this month. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
